ImmunoGen Stock Price, News & Analysis (NASDAQ:IMGN) $29.22 -0.10 (-0.34%) (As of 12/4/2023 ET) Add Compare Share Share Today's Range$29.05▼$29.2850-Day Range$12.46▼$29.3552-Week Range$3.61▼$29.44Volume13.64 million shsAverage Volume5.68 million shsMarket Capitalization$7.78 billionP/E RatioN/ADividend YieldN/APrice Target$25.77 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability ImmunoGen MarketRank™ Stock AnalysisAnalyst RatingHold2.25 Rating ScoreUpside/Downside11.8% Downside$25.77 Price TargetShort InterestBearish12.27% of Shares Sold ShortDividend StrengthN/ASustainability-0.55Upright™ Environmental ScoreNews Sentiment-0.02Based on 52 Articles This WeekInsider TradingSelling Shares$13.42 M Sold Last QuarterProj. Earnings Growth414.29%From $0.07 to $0.36 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.03 out of 5 starsMedical Sector572nd out of 952 stocksPharmaceutical Preparations Industry269th out of 434 stocks 2.1 Analyst's Opinion Consensus RatingImmunoGen has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on 3 buy ratings, 9 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $25.77, ImmunoGen has a forecasted downside of 11.8% from its current price of $29.22.Amount of Analyst CoverageImmunoGen has been the subject of 11 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 1.0 Short Interest Percentage of Shares Shorted12.27% of the outstanding shares of ImmunoGen have been sold short.Short Interest Ratio / Days to CoverImmunoGen has a short interest ratio ("days to cover") of 6.8.Change versus previous monthShort interest in ImmunoGen has recently increased by 30.48%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldImmunoGen does not currently pay a dividend.Dividend GrowthImmunoGen does not have a long track record of dividend growth. Previous Next 4.5 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreImmunoGen has received a 68.55% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for cancer" product. See details.Environmental SustainabilityThe Environmental Impact score for ImmunoGen is -0.55. Previous Next 2.2 News and Social Media Coverage News SentimentImmunoGen has a news sentiment score of -0.02. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.76 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 52 news articles for ImmunoGen this week, compared to 4 articles on an average week.Search Interest48 people have searched for IMGN on MarketBeat in the last 30 days. This is an increase of 60% compared to the previous 30 days.MarketBeat Follows25 people have added ImmunoGen to their MarketBeat watchlist in the last 30 days. This is an increase of 525% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, ImmunoGen insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $13,422,760.00 in company stock.Percentage Held by InsidersOnly 5.07% of the stock of ImmunoGen is held by insiders.Percentage Held by Institutions90.50% of the stock of ImmunoGen is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for ImmunoGen are expected to grow by 414.29% in the coming year, from $0.07 to $0.36 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ImmunoGen is -94.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ImmunoGen is -94.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioImmunoGen has a P/B Ratio of 41.15. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About ImmunoGen Stock (NASDAQ:IMGN)ImmunoGen, Inc., a commercial-stage biotechnology company, focuses on developing and commercializing the antibody-drug conjugates (ADCs) for cancer patients. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), for the treatment of platinum-resistant ovarian cancer; and a cell-surface protein expressed in various epithelial tumors, including ovarian, endometrial, and non-small-cell lung cancers, as well as Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti-FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts.Read More IMGN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IMGN Stock News HeadlinesDecember 5, 2023 | americanbankingnews.comImmunoGen's (IMGN) "Neutral" Rating Reaffirmed at Piper SandlerDecember 4, 2023 | realmoney.thestreet.comImmunoGen downgraded to Neutral from Overweight at Piper SandlerDecember 5, 2023 | Wealthpress (Ad)Trading Experts Call It “The Perfect Tesla Trade”Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.December 4, 2023 | businesswire.comIMMUNOGEN INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of ImmunoGen, Inc. - IMGNDecember 4, 2023 | finance.yahoo.comAre You Looking for a Top Momentum Pick? Why ImmunoGen (IMGN) is a Great ChoiceDecember 4, 2023 | msn.comImmunoGen, AbbVie's $10B Deal Comes At 'Right Time' Analyst Says In Downgrade NoteDecember 4, 2023 | americanbankingnews.comInsider Selling: ImmunoGen, Inc. (NASDAQ:IMGN) SVP Sells $113,154.72 in StockDecember 3, 2023 | americanbankingnews.comImmunoGen (NASDAQ:IMGN) Rating Reiterated by BarclaysDecember 5, 2023 | DTI Trader (Ad)All the trading advice you’ve ever received boils down to thisAll the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.December 3, 2023 | americanbankingnews.comImmunoGen (NASDAQ:IMGN) Downgraded by William BlairDecember 3, 2023 | americanbankingnews.comImmunoGen (NASDAQ:IMGN) Stock Rating Lowered by GuggenheimDecember 3, 2023 | americanbankingnews.comBMO Capital Markets Reiterates Market Perform Rating for ImmunoGen (NASDAQ:IMGN)December 3, 2023 | americanbankingnews.comJefferies Financial Group Reaffirms "Hold" Rating for ImmunoGen (NASDAQ:IMGN)December 2, 2023 | msn.comBarclays Downgrades Immunogen (IMGN)December 2, 2023 | americanbankingnews.comImmunoGen (NASDAQ:IMGN) Sets New 52-Week High at $29.34December 2, 2023 | americanbankingnews.comHC Wainwright Reaffirms Neutral Rating for ImmunoGen (NASDAQ:IMGN)December 1, 2023 | msn.comGuggenheim Downgrades Immunogen (IMGN)December 1, 2023 | seekingalpha.comImmunogen's AbbVie Deal: Key Insights For Investors And TradersDecember 1, 2023 | markets.businessinsider.comMaintaining Hold on ImmunoGen Amid AbbVie Acquisition OfferDecember 1, 2023 | finance.yahoo.comPharma Stock Roundup: ABBV to Buy Immunogen, NVS Ups Mid-Term Sales View & MoreDecember 1, 2023 | msn.comAbbVie to acquire cancer drugmaker ImmunoGen for $10B cash (update)December 1, 2023 | msn.comImmunoGen downgraded on Wall Street expecting AbbVie deal successDecember 1, 2023 | americanbankingnews.comImmunoGen Sees Unusually High Options Volume (NASDAQ:IMGN)November 30, 2023 | realmoney.thestreet.comImmunoGen downgraded to Hold from Buy at CanaccordNovember 30, 2023 | realmoney.thestreet.comImmunoGen downgraded to Market Perform from Outperform at BMO CapitalNovember 30, 2023 | msn.comAbbVie To Buy ImmunoGen, Cancer Drug Maker, In $10.1 Billion Cash DealNovember 30, 2023 | finance.yahoo.comAbbVie to acquire ImmunoGen in $10B dealSee More Headlines Receive IMGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ImmunoGen and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/02/2023Today12/04/2023Fiscal Year End12/31/2023Next Earnings (Estimated)3/06/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:IMGN CUSIP45253H10 CIK855654 Webwww.immunogen.com Phone(781) 895-0600Fax781-895-0611Employees277Year Founded1981Price Target and Rating Average Stock Price Target$25.77 High Stock Price Target$31.26 Low Stock Price Target$16.00 Potential Upside/Downside-11.8%Consensus RatingHold Rating Score (0-4)2.25 Research Coverage12 Analysts Profitability EPS (Most Recent Fiscal Year)($0.31) Trailing P/E RatioN/A Forward P/E Ratio417.43 P/E GrowthN/ANet Income$-222,930,000.00 Net Margins-25.56% Pretax Margin-25.24% Return on Equity-22.11% Return on Assets-13.53% Debt Debt-to-Equity Ratio0.13 Current Ratio5.70 Quick Ratio5.65 Sales & Book Value Annual Sales$108.78 million Price / Sales71.52 Cash FlowN/A Price / Cash FlowN/A Book Value$0.71 per share Price / Book41.15Miscellaneous Outstanding Shares266,260,000Free Float252,764,000Market Cap$7.78 billion OptionableOptionable Beta1.22 Social Links Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesMr. Mark Joseph Enyedy (Age 59)President, CEO & Director Comp: $1.28MMs. Stacy A. Coen M.B.A. (Age 52)Senior VP & Chief Business Officer Comp: $584.04kDr. Michael J. Vasconcelles M.D. (Age 60)Ph.D., Chief Medical Officer Comp: $304.62kMs. Lauren A. White M.B.A. (Age 44)Senior VP & Chief Financial Officer Anabel ChanHead of Investor RelationsMr. Daniel S. Char J.D. (Age 62)Senior VP, Chief Legal Officer & Secretary Ms. Courtney O'KonekSenior Director of Corporate Communications & Investor RelationsMs. Audrey BerganSenior VP & Chief HR OfficerDr. Theresa G. Wingrove (Age 65)Senior Vice President of Regulatory Affairs & Quality Comp: $548.21kMs. Isabel KalofonosSenior VP & Chief Commercial OfficerMore ExecutivesKey CompetitorsMadrigal PharmaceuticalsNASDAQ:MDGLDynavax TechnologiesNASDAQ:DVAXIonis PharmaceuticalsNASDAQ:IONSIronwood PharmaceuticalsNASDAQ:IRWDOPKO HealthNASDAQ:OPKView All CompetitorsInsiders & InstitutionsWellington Management Group LLPBought 3,506,098 shares on 12/1/2023Ownership: 4.980%American Century Companies Inc.Sold 1,207 shares on 11/30/2023Ownership: 0.263%Neo Ivy Capital ManagementBought 31,864 shares on 11/30/2023Ownership: 0.021%Decheng Capital Management III Cayman LLCBought 415,880 shares on 11/29/2023Ownership: 0.156%Theresa WingroveSold 6,792 sharesTotal: $113,154.72 ($16.66/share)View All Insider TransactionsView All Institutional Transactions IMGN Stock Analysis - Frequently Asked Questions Should I buy or sell ImmunoGen stock right now? 12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ImmunoGen in the last year. There are currently 9 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" IMGN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in IMGN, but not buy additional shares or sell existing shares. View IMGN analyst ratings or view top-rated stocks. What is ImmunoGen's stock price target for 2024? 12 Wall Street analysts have issued 12 month price targets for ImmunoGen's shares. Their IMGN share price targets range from $16.00 to $31.26. On average, they anticipate the company's stock price to reach $25.77 in the next year. This suggests that the stock has a possible downside of 11.8%. View analysts price targets for IMGN or view top-rated stocks among Wall Street analysts. How have IMGN shares performed in 2023? ImmunoGen's stock was trading at $4.96 at the beginning of 2023. Since then, IMGN shares have increased by 489.1% and is now trading at $29.22. View the best growth stocks for 2023 here. Are investors shorting ImmunoGen? ImmunoGen saw a increase in short interest during the month of November. As of November 15th, there was short interest totaling 32,660,000 shares, an increase of 30.5% from the October 31st total of 25,030,000 shares. Based on an average daily volume of 4,780,000 shares, the short-interest ratio is currently 6.8 days. View ImmunoGen's Short Interest. When is ImmunoGen's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 6th 2024. View our IMGN earnings forecast. How were ImmunoGen's earnings last quarter? ImmunoGen, Inc. (NASDAQ:IMGN) announced its quarterly earnings results on Thursday, November, 2nd. The biotechnology company reported $0.10 EPS for the quarter, beating the consensus estimate of $0.02 by $0.08. The biotechnology company earned $113.43 million during the quarter, compared to the consensus estimate of $106.98 million. ImmunoGen had a negative trailing twelve-month return on equity of 22.11% and a negative net margin of 25.56%. What ETFs hold ImmunoGen's stock? ETFs with the largest weight of ImmunoGen (NASDAQ:IMGN) stock in their portfolio include Invesco Dorsey Wright Healthcare Momentum ETF (PTH), Virtus LifeSci Biotech Products ETF (BBP), Range Cancer Therapeutics ETF (CNCR), iShares Micro-Cap ETF (IWC), Principal Healthcare Innovators ETF (BTEC), Invesco Nasdaq Future Gen 200 ETF (QQQS), Invesco DWA SmallCap Momentum ETF (DWAS) and iShares Biotechnology ETF (IBB). What is Mark J. Enyedy's approval rating as ImmunoGen's CEO? 16 employees have rated ImmunoGen Chief Executive Officer Mark J. Enyedy on Glassdoor.com. Mark J. Enyedy has an approval rating of 64% among the company's employees. What other stocks do shareholders of ImmunoGen own? Based on aggregate information from My MarketBeat watchlists, some companies that other ImmunoGen investors own include Pfizer (PFE), NVIDIA (NVDA), Micron Technology (MU), Immunomedics (IMMU), Advanced Micro Devices (AMD), AbbVie (ABBV), Gilead Sciences (GILD), OPKO Health (OPK), AT&T (T) and Dynavax Technologies (DVAX). Who are ImmunoGen's major shareholders? ImmunoGen's stock is owned by a variety of retail and institutional investors. Top institutional investors include Redmile Group LLC (6.57%), RA Capital Management L.P. (5.00%), Wellington Management Group LLP (4.98%), FMR LLC (2.17%), Morgan Stanley (1.81%) and Artisan Partners Limited Partnership (1.40%). Insiders that own company stock include David G Foster, Mark J Enyedy, Renee Lentini, Stacy Ann Coen and Theresa Wingrove. View institutional ownership trends. How do I buy shares of ImmunoGen? Shares of IMGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. Does ImmunoGen have any subsidiaries? The following companies are subsidiares of ImmunoGen: Hurricane LLC, ImmunoGen BioPharma (Ireland) Limited, ImmunoGen Europe Limited, and ImmunoGen Securities Corp..Read More This page (NASDAQ:IMGN) was last updated on 12/5/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ImmunoGen, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.